Fact-checked by Grok 2 weeks ago

Retinoid

Retinoids are a class of chemical compounds consisting of natural and synthetic molecules derived from (retinol) or exhibiting structural and functional similarities to it, characterized by a polyene chain with four units in a head-to-tail arrangement and typically featuring a β-ionone . These compounds bind to receptors such as retinoic acid receptors (RARs) and retinoid X receptors (RXRs) to modulate gene transcription, thereby regulating essential biological processes including , , , embryogenesis, , , growth, and immune function. Retinoids are vital for the development and maintenance of multiple organ systems, such as the , heart, kidneys, eyes, and limbs, where disruptions in their signaling pathways can lead to congenital defects or diseases like (APL), metabolic disorders, and skin conditions. Retinoids are classified into four generations based on their chemical evolution and receptor selectivity: first-generation compounds like tretinoin (all-trans-retinoic acid) and (13-cis-retinoic acid), which are non-aromatic and broadly active; second-generation aromatic analogs such as ; third-generation highly selective synthetic retinoids including , , and ; and fourth-generation agents like seletinoid G, designed for minimal and targeted RAR-γ . Biologically, they exert effects through canonical genomic pathways involving /RXR heterodimers that influence over 500 genes, as well as non-genomic mechanisms like rapid signaling and protein retinoylation, which contribute to and repair processes. In , retinoids are cornerstone therapies for acne vulgaris (e.g., achieving up to 87.6% remission rates at 0.5–1.0 mg/kg/day), (e.g., ), photoaging (e.g., tretinoin 0.05% cream reducing wrinkles and after 6–12 months), and pigmentation disorders by promoting epidermal turnover, synthesis, and inhibition of matrix metalloproteinases (MMPs). Beyond skin applications, have significant roles in , with all-trans-retinoic acid (ATRA) inducing in by targeting the PML-RARα fusion protein, often combined with for cure rates exceeding 80%. They also show promise in treating cutaneous T-cell lymphomas (e.g., yielding 44% response rates), , , and preventing oral , while ongoing research explores repurposing for autoimmune diseases and neurodegeneration due to their established safety profiles and properties. Despite efficacy, common adverse effects include skin irritation (, peeling), teratogenicity requiring strict contraception, and risks, prompting development of less irritating formulations like nanoparticles or selective analogs.

Overview and Definition

Definition

Retinoids are a class of natural and synthetic compounds that are structurally and functionally related to (retinol), typically featuring a β-ionone ring and a polyene chain consisting of four units, encompassing retinol itself, (also known as retinaldehyde), , and various derivatives thereof. These substances are structurally related to and exhibit similar biological activities, including roles in cellular processes such as growth and differentiation. Functionally, retinoids are defined as compounds that bind to and activate specific nuclear receptors, namely retinoic acid receptors (RARs) and retinoid X receptors (RXRs), thereby modulating through nuclear signaling pathways. This receptor-mediated mechanism distinguishes retinoids as active signaling molecules in physiological regulation. Unlike , which are plant-derived pigments, retinoids represent the bioactive forms of that arise from the metabolic conversion of provitamin A , such as beta-carotene. The term "retinoid" was coined in the mid-1970s by Michael B. Sporn and colleagues to broadly describe both naturally occurring vitamin A compounds and their synthetic counterparts with comparable structures and functions.

Nomenclature

Retinoids are named systematically according to IUPAC recommendations, using stereoparents such as (an unsaturated derived from ), , and , which imply the all-trans configuration unless specified otherwise. The recommended name for the all-trans form of this is , previously known as retinene or , while alternatives like retinaldehyde are used in nutritional contexts. The carbon numbering system for retinoids follows conventions from carotenoid nomenclature, starting from the beta-ionone ring at one end and proceeding along the polyene chain to the terminal . The beta-ionone ring comprises carbons 1 through 6, with the conjugated chain extending from carbon 7 to at the functional terminus; for example, in , bears the group. This numbering facilitates identification of positions, such as the critical 11-12 . Isomerism in retinoids primarily involves cis-trans configurations around the conjugated double bonds, with the all-trans form serving as the default stereoparent in . The 11-cis isomer is particularly significant biologically, as 11-cis- binds covalently to in cells to form , the light-sensitive pigment in ; upon absorption, it isomerizes to all-trans-, initiating the phototransduction cascade. Cis isomers are denoted by position, such as 11-cis- or using for precision, like (11Z)-. Common names for retinoids often reflect their functional groups and historical association with vitamin A, contrasting with systematic IUPAC names that describe the full structure. For instance, retinol is commonly called vitamin A alcohol, retinal is the aldehyde form, and retinoic acid is the carboxylic acid derivative, whereas systematic names like (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol apply to all-trans-retinol. These common terms remain widely used in biochemical and medical literature for clarity.

Chemical Properties

Molecular Structure

Retinoids share a common molecular scaffold composed of four isoprenoid units linked head-to-tail, resulting in a β-ionone ring connected to a linear polyene chain featuring four conjugated double bonds and a polar at the terminus. This architecture, with the β-ionone ring providing a hydrophobic moiety substituted with three methyl groups, underpins the of retinoids across natural and synthetic variants. The polyene chain consists of a nine-carbon backbone with alternating single and double bonds, forming an extended conjugated π-system that delocalizes electrons and imparts key optical properties. This conjugation enables strong absorption of ultraviolet-visible light at approximately 325 nm, responsible for the yellow-orange coloration observed in retinoids. In the prototypical retinoid retinol (vitamin A alcohol), the molecular formula is C_{20}H_{30}O, and the all-trans configuration features double bonds at positions 2E, 4E, 6E, and 8E along the chain, ensuring maximal planarity and conjugation with the ring's internal double bond. The polar end group varies among retinoids, modulating their overall polarity and solubility. Retinol terminates in a hydroxyl (-OH) group, conferring lipophilicity suitable for membrane association; retinal features an aldehyde (-CHO), which is marginally more polar; and retinoic acid bears a carboxylic acid (-COOH), enhancing hydrophilicity and aqueous solubility through potential ionization at physiological pH. These structural differences in the end group influence transport, binding, and metabolic handling without altering the core conjugated framework.

Physical and Chemical Characteristics

Retinoids exhibit high primarily due to their extended polyene chain, which confers hydrophobic character; for example, has a calculated () of 5.68. This property facilitates their incorporation into membranes and transport via lipoproteins but limits their in aqueous environments. These compounds are inherently unstable, showing sensitivity to light, which induces from the all-trans to cis forms (e.g., 11-cis-retinal from all-trans-retinal with quantum yields of 0.1–0.7 depending on ), oxygen, which promotes oxidation and formation of reactive byproducts, and heat above 60°C, leading to degradation and discoloration. To mitigate these issues, retinoids are typically stored under inert atmospheres (e.g., or ) at temperatures ≤ -20°C in containers or oil-based formulations to minimize exposure. Solubility of retinoids is poor in —for , it is approximately 5 × 10^{-5} mg/mL (~0.05 mg/L)—but they dissolve readily in organic solvents such as , , , , and . This amphiphilic profile, with a polar (e.g., hydroxyl in ) and nonpolar chain, influences their in pharmaceutical and cosmetic applications. properties arise from the conjugated polyene system, enabling UV-Vis absorption; shows a maximum at 325–328 nm in , while all-trans-retinoic absorbs at around 350 nm. Retinoids also display intrinsic , with emitting yellow-green light under extreme UV irradiation, a trait exploited in analytical assays and imaging techniques.

Classification

Natural Retinoids

Natural retinoids encompass the biologically active forms of vitamin A that occur endogenously in living organisms, primarily including , , and . Retinol serves as the main storage and transport form, often esterified with fatty acids to form retinyl esters that are predominantly stored in the liver of vertebrates. , an derivative of retinol, functions as the key in within the . , the oxidized form, acts as a critical signaling molecule that regulates during development and . In addition to these preformed retinoids, provitamin A carotenoids such as and serve as dietary precursors that animals convert into active retinoids through enzymatic processes in the intestine and liver. , the most abundant provitamin A , is symmetrically cleaved by beta-carotene 15,15'-monooxygenase 1 (BCMO1) to yield two of , which can then be reduced to . undergoes central cleavage to produce one of all-trans- and one of α-retinaldehyde, though with lower efficiency than . These conversions provide a vital link between plant-derived pigments and animal retinoid pools, with efficiency varying by and nutritional status. Preformed retinoids like and retinyl esters are predominantly found in animal-derived products, with the highest concentrations in organ meats such as liver, as well as in dairy products, eggs, and . In contrast, provitamin A occur almost exclusively in sources, including orange and green leafy vegetables like carrots, , and sweet potatoes, where beta-carotene predominates. This dichotomy reflects the biosynthetic capabilities of , which produce via the , versus animals, which rely on dietary intake for retinoid supply. Retinoids exhibit remarkable evolutionary across all s, where they underpin essential physiological functions such as , embryonic , and epithelial . The core retinoid signaling pathway, involving receptors and binding proteins like interphotoreceptor retinoid-binding protein (IRBP), traces back to ancient duplications in early lineages, ensuring its indispensability in diverse species from to mammals. This underscores the fundamental role of retinoids in , with disruptions leading to severe developmental defects.

Synthetic Retinoids

Synthetic retinoids are man-made compounds designed to mimic the structure and function of natural retinoids, primarily to enhance therapeutic efficacy while minimizing side effects such as irritation and photodegradation. While many synthetic retinoids feature novel structures not found in nature, some first-generation compounds like tretinoin correspond to naturally occurring , and others like are stereoisomers occurring only in trace amounts biologically. These molecules are engineered through chemical modifications to the polyene chain or terminal rings, aiming for greater stability and targeted binding to retinoic acid receptors (RARs). Unlike purely natural retinoids, synthetic variants are classified into generations based on structural and receptor selectivity. The first generation of synthetic retinoids, developed in the , includes pharmaceutical preparations of such as tretinoin (all-trans-retinoic acid) and synthetic isomers like (13-cis-retinoic acid). Tretinoin, approved for and , binds non-selectively to all subtypes but suffers from instability due to its polyene chain, leading to rapid degradation upon light exposure. , used orally for severe , features a cis configuration at the 13-position to improve and reduce some toxicities associated with the all-trans form. Second-generation synthetic retinoids introduced aromatic rings to replace the unstable polyene chain, enhancing and . , an example from this era, is a monoaromatic derivative designed for treatment, though its long led to accumulation concerns; it was succeeded by acitretin's free-acid form for better elimination. This shift from polyene to aromatic structures marked a key advancement, reducing photoinstability while maintaining retinoid activity. Third-generation synthetic retinoids further refined aromatic designs for receptor selectivity, incorporating naphthoic acid or polyaromatic moieties. , a naphthoic acid derivative, selectively targets RAR-β and RAR-γ, offering improved tolerability for compared to first-generation compounds. , another polyaromatic example, also prefers RAR-β/γ and is used for and . , a distinct third-generation agent, acts as a selective for retinoid X receptors (RXRs), employed in treatment due to its unique heterodimer modulation. The fourth generation emphasizes hyper-selectivity, with (approved in 2019) designed as a potent through precise modifications to the aromatic scaffold, achieving high efficacy for on the face and trunk with minimal off-target effects. Overall, these generational advancements prioritize modifications like cyclization of the polyene chain into stable rings and subtype-specific binding to optimize and reduce systemic toxicity.

Biological Roles

Role in Vision

Retinoids play a central role in through their involvement in phototransduction, by which is converted into electrical signals in the . The key retinoid, 11-cis-retinal—a derivative of —binds covalently to proteins in and photoreceptor cells to form visual s, such as in and iodopsins in cones. This binding occurs via a protonated linkage, stabilizing the pigment in a conformation sensitive to . Upon absorption of a , 11-cis-retinal undergoes a rapid cis-to-trans , converting to all-trans-retinal and initiating a conformational change in the protein. This activated state, known as metarhodopsin II, triggers a G-protein-coupled signaling cascade involving , , and cyclic GMP-gated channels, leading to hyperpolarization of the photoreceptor and signal transmission to cells. The step is highly efficient, with a of approximately 0.65, meaning that about 65% of absorbed photons successfully induce the conformational shift, contributing to the remarkable of that can detect single photons. Following phototransduction, all-trans-retinal is released from the and reduced to all-trans-retinol in the photoreceptor outer segments by enzymes such as retinol dehydrogenase 8 (RDH8). This all-trans-retinol is then transported to the adjacent (RPE), where it is re-esterified by lecithin:retinol acyltransferase (LRAT) into all-trans-retinyl esters. These esters serve as substrates for , an isomerohydrolase that catalyzes the conversion back to 11-cis-retinol, which is subsequently oxidized to 11-cis-retinal by 11-cis-retinol dehydrogenase 5 (RDH5). The regenerated 11-cis-retinal is shuttled back to the photoreceptors via the interphotoreceptor retinoid-binding protein (IRBP), completing the and enabling continuous pigment renewal essential for sustained vision. Disruptions in retinoid availability or the impair formation and regeneration, leading to conditions such as night blindness (). In , insufficient 11-cis-retinal limits visual pigment synthesis, particularly in , resulting in delayed dark adaptation and reduced low-light sensitivity. Similarly, mutations in genes encoding visual cycle enzymes, like RDH5, cause fundus albipunctatus, a form of stationary night blindness characterized by prolonged recovery after light exposure due to slowed 11-cis-retinal production.

Role in Development and Differentiation

Retinoids, particularly (), play a pivotal role in embryonic by acting as morphogens that establish signaling gradients essential for patterning the anterior-posterior (A-P) axis. In embryos, RA gradients formed through localized and degradation influence the spatiotemporal expression of developmental genes, thereby guiding tissue specification and . RA regulates clusters, which are critical transcription factors organized in collinear domains along the A-P axis. As a , RA induces the expression of 3'-Hox genes (such as , , and ) in a concentration-dependent manner, promoting hindbrain segmentation into rhombomeres and specifying cranial cell fates. This regulation ensures proper positioning of structures like the branchial arches and , with disruptions altering Hox expression patterns and leading to axial defects. The core signaling mechanism involves RA binding to retinoic acid receptors (RARs), which heterodimerize with retinoid X receptors (RXRs) to form RA-RAR complexes. These complexes bind to retinoic acid response elements (RAREs) in the promoter regions of target genes, recruiting coactivators to initiate transcription of developmental regulators such as Hox genes and those involved in cell fate determination. In the absence of RA, RAR-RXR binds RAREs with corepressors to maintain gene repression, highlighting RA's role in switching from repression to activation during differentiation. In , RA promotes lineage commitment by directing pluripotent cells toward specific fates. For neuronal , RA treatment of human embryonic stem cells or neural progenitors enhances the expression of neurogenic markers like Nestin and β-III , facilitating the transition from progenitors to mature neurons. Similarly, in hematopoietic , RA signaling from human pluripotent stem cells boosts the generation of primitive blood progenitors while suppressing non-hematopoietic lineages, underscoring its instructive role in multilineage specification. Excess RA exhibits teratogenic effects by perturbing these developmental gradients, particularly in limb and craniofacial regions. High RA levels inhibit Cyp26 enzymes, which normally degrade RA to maintain low concentrations in anterior domains, resulting in ectopic signaling that disrupts proximodistal limb patterning and causes malformations like or . In mouse models, Cyp26b1 deficiency mimics excess RA phenotypes, confirming that precise RA clearance is vital for preventing anterior shifts in Hox expression and ensuring normal skeletogenesis.

Role in Immunity and Reproduction

(RA), the active metabolite of , plays a pivotal role in modulating immune responses, particularly in promoting mucosal immunity through its actions on (GALT). In the intestinal environment, RA produced by CD103+ dendritic cells induces the expression of gut-homing receptors such as α4β7 and CCR9 on T and B lymphocytes, facilitating their migration to mucosal sites and enhancing IgA by B cells, which is crucial for barrier defense against pathogens. This process supports and in the gut, where RA also promotes the of + regulatory T cells (Tregs) in conjunction with transforming growth factor-β (TGF-β), thereby balancing pro- and anti-inflammatory responses. Additionally, RA exerts anti-inflammatory effects by suppressing Th17 cell under steady-state conditions and inhibiting proinflammatory cytokine production, such as TNF-α and IL-12, in macrophages via downregulation of signaling. In the context of reproduction, retinoids are indispensable for gametogenesis in both males and females. Retinol, transported to the testes, is converted to , which drives spermatogonial differentiation and the initiation of by upregulating Stra8 expression in spermatogonia, synchronizing the seminiferous epithelium cycle and ensuring continuous sperm production. Vitamin A deficiency disrupts this process, leading to arrest at the undifferentiated spermatogonial stage and subsequent in mammals, as demonstrated in models where RA supplementation restores . Similarly, in females, RA is essential for ovarian follicle development; it promotes oocyte maturation and granulosa cell function postnatally, enhancing follicle growth and preventing through pathways involving follicle-stimulating hormone (FSH) synergy. Deficiency results in impaired and oocyte arrest, contributing to , with evidence from mammalian studies showing RA's necessity for germ cell survival and progression. Retinoids also contribute to skin barrier integrity as part of innate immunity, maintaining epithelial cohesion and defenses. RA regulates differentiation and proliferation, preserving the structural barrier against environmental insults, while compromises this integrity, increasing infection susceptibility. Furthermore, retinoids induce the production of , such as resistin-like molecule α (RELMα) in and sebocytes, which disrupts bacterial membranes of pathogens like and ; this expression is RAR-dependent and enhanced by , shaping the microbiota and bolstering resistance to invasion. Systemically, retinoids influence metabolic and skeletal through (RXR) heterodimers. In , RA inhibits preadipocyte differentiation by activating RXR heterodimers with γ (PPARγ), suppressing key transcription factors like C/EBPβ and promoting anti-adipogenic genes such as PREF-1 and , thereby limiting fat accumulation and mitigating risk. In bone , RXR heterodimers with retinoic acid receptors (RARs) regulate osteoclastogenesis; RA stimulates RANKL expression via RARα/RXR, enhancing while inhibiting mineralization, with excessive levels linked to cortical bone loss in preclinical models. These actions underscore retinoids' broader role in integrating immune, reproductive, and metabolic physiology.

Sources and Metabolism

Dietary Sources

Retinoids, essential for various physiological functions, are obtained primarily through dietary sources in the form of preformed (retinol and retinyl esters) or provitamin A like beta-carotene. The nutritional content of these compounds is standardized using retinol activity equivalents (RAE), where 1 μg RAE equals 1 μg or 12 μg dietary beta-carotene, accounting for differences in and conversion efficiency. Animal-derived foods provide preformed retinoids with high , typically exceeding 80%, making them efficient sources for meeting needs. Liver is among the richest, with beef liver containing approximately 6,500 μg RAE per 100 g, while eggs offer about 150 μg RAE per 100 g and dairy products like whole provide around 50 μg RAE per 100 g, often higher in fortified varieties. Plant-based sources supply provitamin A carotenoids, which the body converts to active retinoids, though and rates are lower, ranging from 10% to 30% depending on food matrix and dietary fat intake. Carrots contain about 8,000 μg beta-carotene per 100 g, and sweet potatoes provide around 8,300 μg beta-carotene per 100 g in baked form, serving as key contributors in vegetarian diets. The recommended dietary allowance (RDA) for is 900 μg RAE per day for adult men and 700 μg RAE per day for adult women, with higher needs during and . Deficiency remains a significant issue in developing countries, affecting approximately 190 million preschool-age children and increasing risks of blindness, infections, and mortality, particularly in regions with limited access to diverse foods.
Food SourceTypeApproximate Content per 100 gBioavailability Notes
Beef liver (cooked)Animal (preformed)6,500 μg RAE>80% absorption
Eggs (whole, raw)Animal (preformed)150 μg RAE>80% absorption
Whole milkAnimal (preformed)50 μg RAE>80% absorption; fortified options higher
Carrots (raw)Plant (provitamin A)8,000 μg beta-carotene10-30% conversion to retinol
Sweet potatoes (baked)Plant (provitamin A)8,300 μg beta-carotene10-30% conversion to retinol

Biosynthesis and Metabolism

Retinoids are primarily derived from dietary provitamin A , such as , which undergo enzymatic cleavage in the to initiate endogenous . The enzyme β-carotene 15,15'-monooxygenase 1 (BCO1) catalyzes the central cleavage of at the 15,15' double bond, yielding two molecules of all-trans-retinal in a reaction requiring molecular oxygen and iron as cofactors. This step is the main pathway for converting plant-derived into bioavailable retinoids, with BCO1 expression predominantly in the intestinal mucosa to facilitate absorption. The central metabolite retinal participates in reversible and irreversible interconversions to form other retinoids. Retinal is reduced to retinol by NADP(H)-dependent retinol dehydrogenases, such as those in the short-chain dehydrogenase/reductase family, or oxidized back to retinal from retinol via enzymes like alcohol dehydrogenase 4 (ADH4) or retinol dehydrogenase 10 (RDH10), which utilize NAD+ as a cofactor in a reversible equilibrium. For retinoic acid production, retinal is irreversibly oxidized to all-trans-retinoic acid by retinaldehyde dehydrogenases (RALDHs), specifically the ALDH1A family members (RALDH1, RALDH2, and RALDH3), using NAD+ and exhibiting high substrate specificity for retinaldehyde with Km values around 0.3–1 μM. These interconversions occur in various tissues, with RDH10 and RALDH2 playing critical roles in embryonic retinoic acid synthesis. Retinol is stored in the liver as retinyl esters to maintain during periods of dietary insufficiency. In hepatic stellate cells, which account for 80–90% of total liver retinoid stores, retinol is esterified with long-chain fatty acids by :retinol acyltransferase (LRAT) to form retinyl esters within droplets. Mobilization occurs through of these esters by retinyl ester hydrolases, releasing retinol that binds to 4 (RBP4), a 21-kDa protein synthesized in hepatocytes, for to peripheral tissues via the bloodstream. This RBP4-mediated delivery ensures targeted distribution while preventing free retinol toxicity. Retinoic acid, the most active retinoid, undergoes to prevent accumulation and regulate signaling. The enzymes of the CYP26 family (CYP26A1, CYP26B1, and CYP26C1) initiate by ω- and ω-1 , producing 18-hydroxy-retinoic acid and 4-hydroxy-retinoic acid, respectively; the latter is further oxidized to 4-oxo-retinoic acid. These polar metabolites are subsequently glucuronidated by UDP-glucuronosyltransferases for biliary excretion, with CYP26A1 exhibiting high affinity (Km ≈ 50 nM) and tissue-specific expression to fine-tune local retinoic acid gradients. This pathway is essential for embryonic patterning and adult tissue maintenance.

Pharmacological Aspects

Pharmacokinetics

Retinoids, both natural and synthetic, exhibit distinct pharmacokinetic profiles influenced by their , with oral forms achieving systemic exposure and topical applications primarily acting locally. Absorption of oral retinoids, such as retinol esters from supplements, occurs efficiently in the , reaching 60-80% when co-administered with dietary , which facilitates formation and uptake via transporters like and SR-BI. This process depends on salts and pancreatic for of esters to free before incorporation into chylomicrons. In contrast, topical retinoids like tretinoin demonstrate limited percutaneous absorption, typically less than 1-5% entering systemic circulation, though can enhance penetration for localized effects without significant accumulation. Following absorption, retinoids are distributed via plasma binding proteins; retinol specifically complexes with and to prevent toxicity and enable delivery to target tissues. Approximately 90-95% of body stores accumulate in the liver as retinyl esters in hepatic stellate cells, with additional sequestration in , skin, and other organs, allowing prolonged availability that can sustain needs for months to years. Synthetic retinoids like show high protein binding (>99.9% to ) and similar tissue , though they lack the extensive esterification seen in endogenous retinol. Metabolism of retinoids primarily occurs in the liver and target tissues, where is oxidized stepwise to retinaldehyde and then all-trans-retinoic acid via and , with enzymes (e.g., CYP26) regulating levels to avoid excess. Synthetic analogs like undergo hepatic biotransformation via CYP2C8, , , and to active metabolites such as 4-oxo-isotretinoin. for is approximately 12 hours, but hepatic stores extend functional persistence to several months; for , the elimination averages 18 hours, with its major metabolite at 38 hours. Excretion of retinoids involves both biliary and renal routes, with unmetabolized forms and conjugates predominantly eliminated via after biliary , accounting for over 70% of clearance. Polar metabolites, such as retinoyl β-, are excreted in , though this represents a minor pathway (<30%) due to efficient enterohepatic recirculation. For topical applications, minimal systemic absorption results in negligible urinary or fecal excretion beyond local skin turnover.

Mechanism of Action

Retinoids primarily exert their effects through binding to nuclear receptors, which regulate gene transcription. The two main receptor families are the retinoic acid receptors (), consisting of three isoforms (, , and ), and the retinoid X receptors (), also with three isoforms (, , and ). All-trans-retinoic acid (), the primary active retinoid, binds with high affinity to , while 9-cis-retinoic acid binds to both and . These receptors function as ligand-dependent transcription factors; in the absence of ligand, heterodimers repress target gene expression by recruiting corepressor complexes, but upon retinoid binding, they undergo conformational changes that promote dissociation of corepressors, recruitment of coactivators, and activation of transcription. The activated heterodimers bind to specific DNA sequences known as retinoic acid response elements () for or for homodimers, thereby modulating the expression of retinoid-responsive genes. At the transcriptional level, retinoids induce cellular processes such as differentiation and apoptosis by upregulating key regulatory genes. For instance, ATRA promotes cell cycle arrest by increasing the expression of the cyclin-dependent kinase inhibitor , which inhibits cyclin E/CDK2 complexes and halts progression from G1 to S phase. This upregulation contributes to retinoid-induced differentiation in various cell types. Additionally, retinoids can trigger apoptosis through transcriptional activation of pro-apoptotic genes, often involving that further amplify p21 expression and caspase activation. Beyond genomic actions, retinoids mediate rapid non-genomic effects through membrane-associated signaling pathways. Retinol bound to retinol-binding protein interacts with the transmembrane receptor , facilitating cellular uptake and simultaneously activating intracellular signaling cascades such as JAK/STAT phosphorylation, independent of nuclear receptor involvement. This bidirectional transport and signaling via allow for quick cellular responses to extracellular retinoid levels. Synthetic retinoids exhibit enhanced selectivity for specific receptor isoforms, improving therapeutic profiles. For example, adapalene acts as a selective agonist for RARβ and RARγ, with minimal affinity for RARα, which reduces off-target effects compared to pan-RAR agonists like ATRA. This isoform-specific binding influences the pattern of gene activation, favoring certain transcriptional outcomes.

Clinical Applications

Dermatological Uses

Retinoids play a central role in the dermatological management of through both topical and systemic administration. Topical agents such as normalize abnormal keratinization within the pilosebaceous unit, preventing the formation of microcomedones that serve as precursors to acne lesions, while also indirectly reducing the proliferation of Propionibacterium acnes by altering the follicular microenvironment. Oral extends these benefits by potently suppressing sebum production, exhibiting antimicrobial effects against P. acnes, and modulating inflammation, making it particularly suitable for moderate-to-severe cases. Clinical trials underscore the efficacy of retinoids in acne treatment, with topical tretinoin 0.05% lotion yielding mean percent reductions of 58.6% in inflammatory lesions and 51.4% in noninflammatory lesions after 12 weeks of once-daily use in patients with moderate acne. Similarly, oral isotretinoin achieves substantial lesion clearance, with network meta-analyses of randomized controlled trials reporting approximately 48% overall reduction in total lesions at 12 weeks across diverse patient populations. In addressing photoaging, topical retinoids like retinol promote dermal remodeling by stimulating the synthesis of collagen types I and III through activation of fibroblast pathways, including TGF-β/Smad signaling, which counteracts ultraviolet-induced matrix degradation and enhances skin structure. Application of 0.1% stabilized retinol, for example, has demonstrated significant improvements in skin elasticity and firmness, alongside visible reductions in fine wrinkles, in double-blind vehicle-controlled studies involving photodamaged skin over 8 weeks. For psoriasis, particularly plaque-type variants, oral acitretin exerts anti-proliferative effects by binding retinoic acid receptors to normalize keratinocyte differentiation and inhibit hyperproliferation, leading to decreased plaque thickness, scaling, and erythema. Clinical evidence supports its use as monotherapy or in combination therapy, with noticeable plaque reduction emerging within 4-6 weeks and maximal benefits often requiring 3-4 months of treatment at doses of 25-50 mg daily.

Oncological Uses

Retinoids have established a prominent role in oncology, particularly through their ability to induce differentiation in malignant cells, leading to remission in certain hematologic malignancies and applications in chemoprevention and treatment of solid tumors. In acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by the t(15;17) translocation, all-trans-retinoic acid (ATRA) serves as a cornerstone of therapy by targeting the PML-RARα fusion protein to promote differentiation of promyelocytes. When combined with arsenic trioxide (ATO), this regimen achieves complete remission in nearly all patients and cure rates approaching 90%, markedly improving outcomes compared to chemotherapy alone. For chemoprevention, 13-cis-retinoic acid (isotretinoin) has been investigated to reduce the incidence of second primary tumors in patients with squamous-cell carcinoma of the head and neck following curative surgery or radiation. A landmark randomized trial demonstrated that high-dose isotretinoin significantly lowered the risk of new aerodigestive tract cancers, though subsequent studies with lower doses showed limited efficacy, highlighting the importance of dosing in preventive strategies. In solid tumors, bexarotene, a selective retinoid X receptor (RXR) agonist, is approved for the treatment of cutaneous T-cell lymphoma (CTCL), particularly in refractory or persistent cases. By activating RXR heterodimers, bexarotene induces apoptosis and differentiation in malignant T-cells, achieving objective response rates of 45-54% in phase II and III trials, with durable remissions in advanced disease stages. Resistance to retinoid therapy, a key challenge in oncology, often arises from overexpression of cytochrome P450 enzymes such as , which metabolizes retinoic acid into polar derivatives, thereby reducing intracellular levels and attenuating differentiation signals in tumors like APL. This mechanism contributes to relapse by diminishing the bioavailability of active retinoids, prompting research into inhibitors of CYP26 to enhance therapeutic efficacy.

Other Medical Uses

Retinoids have been investigated for their role in supporting visual function in inherited retinal degenerative diseases. In patients with , a progressive disorder characterized by photoreceptor degeneration, oral supplementation with in the form of retinyl palmitate has been studied for aiding the visual cycle, which involves the recycling of retinoids essential for phototransduction in rod cells. Although an older randomized clinical trial suggested potential preservation of retinal function, as of 2025, assessments by the and other reviews find no high-quality evidence supporting the effectiveness of vitamin A supplementation for slowing RP progression. Supplementation is recommended only under medical supervision due to risks of . In the context of immunodeficiency, retinoid analogs, particularly all-trans-retinoic acid (ATRA) derivatives, show promise in modulating immune responses and addressing latent viral reservoirs. For HIV-1 infection, isotretinoin, a synthetic retinoid, has been shown to enhance latency reversal by reactivating dormant proviruses in CD4+ T cells when combined with interleukin-15, promoting the elimination of translation-competent latent reservoirs without excessive T-cell activation. Preclinical studies indicate that ATRA analogs activate the latent HIV reservoir through retinoic acid receptor signaling, potentially synergizing with antiretroviral therapy to reduce persistent viral loads. In autoimmune conditions such as systemic lupus erythematosus (SLE), ATRA exhibits immunomodulatory effects by suppressing pro-inflammatory cytokine production and promoting regulatory T-cell differentiation, leading to reduced disease activity. Clinical reports document rapid improvements in lupus nephritis symptoms, including decreased proteinuria and stabilized renal function, in patients treated with ATRA alongside corticosteroids, highlighting its steroid-sparing potential. Etretinate, a second-generation retinoid, has been employed in the management of severe ichthyosiform disorders, such as , where it normalizes keratinization and reduces scaling by binding to to regulate epidermal differentiation. Despite its efficacy in improving skin barrier function and quality of life in pediatric and adult patients, long-term use is constrained by significant toxicity, including skeletal hyperostosis and premature epiphyseal closure, observed in up to 20% of treated children after prolonged administration. These adverse bone effects, characterized by periosteal reactions and ligament ossifications, necessitate regular radiographic monitoring and often limit therapy to short courses or lower doses, with (etretinate's metabolite) preferred when possible due to a shorter half-life. Emerging applications of retinoid receptor antagonists underscore their potential beyond agonists in reproductive medicine. YCT-529, a selective retinoic acid receptor alpha (RARα) antagonist, has shown contraceptive efficacy in preclinical models by disrupting retinoic acid signaling critical for spermatogenesis, reversibly reducing sperm counts to infertile levels in mice and non-human primates without affecting testosterone or libido. Preclinical studies as of 2025 demonstrated up to 99% efficacy in preventing pregnancy in mouse mating trials, with full fertility recovery within weeks of discontinuation, positioning it as a novel non-hormonal male contraceptive candidate entering phase I trials.

Safety Profile

Toxicity and Side Effects

Retinoids, as derivatives of vitamin A, can lead to hypervitaminosis A when intake exceeds safe levels, resulting in a range of acute and chronic toxicities. Chronic exposure to retinol exceeding the tolerable upper intake level of 3,000 μg retinol activity equivalents (RAE) per day may cause symptoms such as headache due to increased intracranial pressure, fatigue, and bone pain. Hepatotoxicity is a prominent concern in chronic hypervitaminosis A, manifesting as hepatomegaly, elevated liver enzymes, and potential progression to fibrosis or cirrhosis, particularly with prolonged intake above 8,000 RAE/day. Mucocutaneous side effects are among the most common adverse reactions to systemic retinoids like isotretinoin, often dose-dependent and affecting the skin and mucous membranes. These include dry skin (xerosis), cheilitis (lip inflammation), and xerostomia (dry mouth), which occur in up to 90% of patients on isotretinoin therapy due to impaired barrier function and increased transepidermal water loss. Hypertriglyceridemia, another frequent metabolic effect, develops in approximately 50% of patients treated with isotretinoin, potentially leading to pancreatitis in severe cases if unmanaged. Teratogenicity represents a severe risk associated with retinoids, particularly during pregnancy, where exposure to compounds like isotretinoin or all-trans retinoic acid can cause profound developmental abnormalities. These drugs are classified as pregnancy category X by the FDA, indicating a high risk of fetal harm, with in utero exposure linked to craniofacial defects such as microtia, anotia, and micrognathia in 20-35% of cases. The mechanism involves disruption of retinoic acid signaling critical for embryonic patterning, resulting in additional malformations including cardiac and central nervous system anomalies. Dose-dependent adverse effects are prominent with topical retinoids, where irritation arises from direct epidermal responses. Retinoid dermatitis, characterized by erythema, scaling, burning, and pruritus, stems from retinoid-induced epidermal hyperplasia mediated by activation of retinoic acid receptors and elevated heparin-binding epidermal growth factor-like growth factor (HB-EGF), leading to increased keratinocyte proliferation and barrier disruption. This irritation typically resolves upon dose reduction or discontinuation but can limit treatment adherence.

Contraindications and Precautions

Retinoids, particularly , are absolutely contraindicated during pregnancy due to their potent teratogenic effects, which can cause severe birth defects in the fetus. To mitigate this risk, the mandates that females of childbearing potential use two effective forms of contraception simultaneously, undergo a 30-day waiting period with contraception before starting therapy, and submit to monthly pregnancy testing. Similar precautions, including dual contraception, are recommended for other systemic retinoids like , even without a formal program like iPLEDGE. In patients with hyperlipidemia, retinoids such as isotretinoin should be used with caution or avoided, especially if baseline triglycerides exceed 200 mg/dL, as they can exacerbate lipid abnormalities. Baseline fasting lipid profiles are essential before initiating therapy, with periodic monitoring recommended every 1-2 months to detect elevations in triglycerides, cholesterol, or LDL levels. If significant hypertriglyceridemia develops (e.g., >2.6 mmol/L or approximately 230 mg/dL), dose adjustment or discontinuation may be necessary, alongside closer follow-up. For individuals with hepatic impairment, retinoids require dose reduction and vigilant monitoring, as they can elevate liver enzymes and potentially worsen liver function. Baseline liver function tests (LFTs), including ALT, AST, and bilirubin, should be obtained prior to starting therapy, with repeat testing monthly or as clinically indicated to assess for hepatotoxicity. Key drug interactions with retinoids include concurrent use with tetracyclines, which can increase the risk of pseudotumor cerebri (benign intracranial hypertension) due to additive effects on intracranial pressure. This combination is generally contraindicated, and alternative antibiotics should be considered if antimicrobial therapy is needed. Additionally, vitamin A supplements should be avoided during retinoid therapy to prevent additive hypervitaminosis A and related toxicities.

History and Research

Historical Development

The discovery of as a fat-soluble essential for growth began in 1913, when Elmer V. McCollum and Marguerite Davis at the University of Wisconsin identified a growth-promoting factor in and egg yolk that was absent in certain plant oils, distinguishing it from water-soluble factors and marking the first recognition of a fat-soluble vitamin. Their experiments with rats demonstrated that this "fat-soluble A" prevented nutritional deficiencies, laying the foundation for understanding its role in mammalian . In the 1930s, Swiss chemist Paul Karrer elucidated the chemical structure of , identifying the β-ionone ring as a key component and establishing its relationship to like , for which he received the in 1937. Building on this, the first of , the primary alcohol form of , was achieved in 1947 through industrial efforts led by Hoffmann-La Roche, enabling large-scale production and further biochemical studies. By the 1950s, research advanced the understanding of vitamin A's function in , with demonstrating that is a precursor to , the light-sensitive pigment in rod cells, through experiments showing its regeneration cycle in the . , culminating in his 1967 in or Medicine shared with Ragnar Granit and Haldan Keffer Hartline, highlighted how leads to night blindness by impairing formation. The marked a pivotal shift with the introduction of the term "retinoid" by Michael B. Sporn and colleagues in 1976 to encompass both natural compounds and synthetic analogs sharing structural and functional similarities, broadening research into their therapeutic potential beyond nutrition. This era saw the development of key synthetic retinoids, such as tretinoin (all-trans ), which received U.S. approval in 1971 for topical treatment of vulgaris, establishing it as the first retinoid-based therapy for dermatological conditions.

Recent Advances

In recent years, fourth-generation retinoids have advanced dermatological treatments by enhancing selectivity and minimizing systemic exposure. , approved by the FDA in 2019 for vulgaris in patients aged 9 and older, exemplifies this progress as a potent and selective agonist of the receptor gamma (RAR-γ), which is predominantly expressed in epidermal . This receptor specificity allows trifarotene to target lesions with reduced irritation and lower risk of systemic side effects compared to earlier retinoids, as demonstrated in real-world studies showing efficacy in treating sequelae like post-inflammatory and atrophic scars. By 2025, clinical evidence has supported its integration into multimodal management, highlighting improved tolerability for long-term use. Emerging applications of retinoid receptor modulation extend to reproductive health, with YCT-529 representing a breakthrough in non-hormonal male contraception. This selective RAR-α antagonist, developed to inhibit without affecting hormones, entered phase 1 clinical trials in 2025 and demonstrated safety in humans while reversibly reducing sperm counts to levels in preclinical models. In non-human , oral administration of YCT-529 achieved over 99% contraception efficacy in mating studies, with full fertility recovery post-treatment, underscoring its potential as an on-demand alternative to traditional methods. Retinoids have also shown promise in addressing latent viral reservoirs and age-related skin changes. In 2025 studies, retinol-binding protein 4 (RBP4), a key transporter in the retinoid pathway, was identified as a natural latency-reversing agent that reactivates dormant HIV-1 reservoirs via JAK/STAT5 and JNK signaling pathways, offering a host-directed toward viral cure without toxicity seen in other activators. Concurrently, combinations of retinol with ginsenoside CK have demonstrated synergistic anti-photoaging effects by enhancing antioxidant defenses and reducing UVA-induced in human , with in vivo models confirming reduced irritation and improved skin barrier function. Advances in regenerative biology further illuminate retinoid roles in tissue repair and . Research in 2025 revealed that enzymatic breakdown of by CYP26B1 is essential for establishing proximodistal positional identity during limb regeneration, where inhibiting this process leads to proximalization errors, providing insights into patterning mechanisms applicable to mammalian . In pancreatic contexts, retinoid signaling has been linked to disease progression, with all-trans (ATRA) modulating Notch3 expression in stellate cells to suppress fibrosis in models, while dysregulation contributes to islet dysfunction in . These findings highlight retinoids' evolving therapeutic potential in regenerative and metabolic disorders.

References

  1. [1]
    Retinoids: active molecules influencing skin structure formation in ...
    Retinoids are a class of compounds derived from vitamin A or showing structural and/or functional similarities to vitamin A.
  2. [2]
    Retinoic Acid Signaling Pathways in Development and Diseases
    Retinoids are essential in the development and function of several organ systems; however, deregulated retinoid signaling can contribute to serious diseases.
  3. [3]
    Structure–Activity Relationships and Therapeutic Applications of ...
    Retinoids comprise a diverse class of chemical compounds derived from vitamin A. Their impact on biological systems is extensive, largely due to their ...
  4. [4]
    Retinoids in the treatment of skin aging: an overview of clinical ... - NIH
    Retinoids are required for a vast number of biological processes. In particular, they are involved in embryogenesis, reproduction, vision, growth, inflammation, ...
  5. [5]
    Retinoid - an overview | ScienceDirect Topics
    “Retinoid” refers to the naturally occurring compounds with vitamin A activity and to synthetic analogues of retinol.
  6. [6]
    Retinoids - LiverTox - NCBI Bookshelf - NIH
    Nov 10, 2020 · Retinoids are both natural and synthetic derivatives of vitamin A, several of which have been developed for medical uses, largely to replace ...Missing: definition | Show results with:definition
  7. [7]
    Retinoids | Fitzpatrick's Dermatology, 9e | AccessMedicine
    A retinoid is any molecule that by itself or through metabolic conversion binds to and activates retinoic acid receptors. · Retinoid receptors are ligand- ...
  8. [8]
    Retinoid X receptor (RXR) within the RXR-retinoic acid receptor ...
    Retinoic acid receptor (RAR) and retinoid X receptor (RXR) form heterodimers and regulate retinoid-mediated gene expression.
  9. [9]
    Vitamin A and Carotenoids - Health Professional Fact Sheet
    Mar 10, 2025 · The human diet contains two sources for vitamin A: preformed vitamin A (retinol and retinyl esters) and provitamin A carotenoids [1,5].Missing: distinction | Show results with:distinction
  10. [10]
    Nomenclature of Retinoids
    The compound (2) also known as vitamin A aldehyde, vitamin A1 aldehyde, retinene or retinene1 should be designated retinal (see note 1) or, if liable to be ...Preamble · Ret-2. Stereoparents · Ret-4. Modification of...
  11. [11]
    Chemistry of the Retinoid (Visual) Cycle | Chemical Reviews
    In this review we focus on the involvement of retinoids in supporting vision via light-sensitive rod and cone photoreceptor cells in the retina.
  12. [12]
    11-cis and all-trans retinols can activate rod opsin - NIH
    Upon absorption of a photon, the covalently bound 11-cis retinal isomerizes to the all-trans form enabling rhodopsin to activate transducin, its G protein.
  13. [13]
    Retinol | C20H30O | CID 445354 - PubChem - NIH
    Retinol is converted to RA by the action of two types of enzyme, retinol dehydrogenases and retinal dehydrogenases. In the nucleus RA acts as a ligand to ...
  14. [14]
    Retinoid nanoparticulates: Approachable gateway for acne treatment
    Retinol and retinoic acid which have an alcoholic group and a carboxylic group respectively are soluble in alcoholic solvents such as methanol, ethanol, and ...
  15. [15]
    (PDF) Properties of Retinoids: Structure, Handling, and Preparation
    Aug 10, 2025 · Retinoids are unstable compounds being readily oxidized and/or isomerized to altered compounds, especially in the presence of oxidants ...
  16. [16]
    Vitamin A | Linus Pauling Institute | Oregon State University
    Retinol can be converted by the body to retinal, which can be in turn be oxidized to retinoic acid, the form of vitamin A known to regulate gene transcription.
  17. [17]
    Vitamin A Update: Forms, Sources, Kinetics, Detection, Function ...
    Some of the most well-known carotenoids are β-carotene, α-carotene, lutein, lycopene and cryptoxanthin. Carotenoids are tetraterpenoids in contrast to animal- ...3. Vitamin A... · 4. Vitamin A Functions · 6. Vitamin A DeficiencyMissing: distinction | Show results with:distinction<|control11|><|separator|>
  18. [18]
    Vitamin A - The Nutrition Source
    The two main forms of vitamin A in the human diet are preformed vitamin A (retinol, retinyl esters), and provitamin A carotenoids such as alpha-carotene and ...
  19. [19]
    Provitamin A metabolism and functions in mammalian biology
    Provitamin A carotenoids such as β-carotene are the major source for retinoids (vitamin A and its derivatives) in the human diet.
  20. [20]
    Highest levels of retinol found in animal livers and of β-carotene in ...
    Dec 30, 2022 · Highest levels of retinol were found in liver and liver-based food. High β-carotene levels occurred in orange/green leafy vegetables and fruit nectars.
  21. [21]
    Evolution of Retinoid and Steroid Signaling: Vertebrate ...
    We investigated the evolution of these genetic networks by conducting an exhaustive survey of components of the retinoid and steroid pathways in the genome of ...
  22. [22]
    Bacterial origin of a key innovation in the evolution of the vertebrate ...
    Apr 10, 2023 · We demonstrate that IRBP, a highly conserved and essential retinoid shuttling protein, arose from a bacterial gene that was acquired, duplicated ...
  23. [23]
    Retinoic acid signaling and the evolution of chordates - PMC
    We show that some of the control mechanisms governing RA-mediated patterning are quite conserved among vertebrates and between vertebrates and invertebrate ...
  24. [24]
    A Clinician's Guide to Topical Retinoids - PMC - NIH
    In general, retinoids are divided into 4 generations based on their molecular structure and receptor selectivity. Topical retinoids are divided into 6 classes.
  25. [25]
    Clinical Pharmacology of 3 Generations of Retinoids
    It is the purpose of this paper to review some of these aspects. One may distinguish at least 3 genera tions of retinoids (table I). Of course this.
  26. [26]
    A selective retinoid X receptor agonist bexarotene (LGD1069 ...
    Feb 21, 2006 · The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours.
  27. [27]
  28. [28]
  29. [29]
    Phototransduction in Rods and Cones by Yingbin Fu - Webvision
    Jul 30, 2018 · Quantum efficiency of visual pigments is wavelength-independent at ~ 0.7 in the spectrum of visible light whereas it falls to about 0.25 for ...
  30. [30]
  31. [31]
  32. [32]
  33. [33]
    Retinoic acid signalling during development
    Mar 1, 2012 · RAR/RXRs can bind RAREs even in the absence of ligand, thereby recruiting co-repressor complexes and maintaining target gene repression (Fig. 3) ...
  34. [34]
    Retinoic acid, RARs and early development - PMC - NIH
    Binding of RA to RARs results in a conformational shift in RAR that alters its ability to bind nuclear receptor coactivators (NCOA) or nuclear receptor ...
  35. [35]
    Genetics and functions of the retinoic acid pathway, with special ...
    Dec 3, 2019 · Retinoic acid (RA) is a potent morphogen required for embryonic development. RA is formed in a multistep process from vitamin A (retinol).
  36. [36]
    Retinoids and Hox genes - PubMed
    Retinoids can affect the expression of Hox genes in cells lines and embryonic tissues; the hindbrain and branchial region of the head are particularly sensitive ...
  37. [37]
    Retinoic Acid Regulates Hematopoietic Development from Human ...
    Feb 10, 2015 · Decreased Retinoic Acid Signaling Increases the Generation of Hematopoietic Progenitors from Human Pluripotent Stem Cells. Using a 16-day ...
  38. [38]
    Retinoic acid induced the differentiation of neural stem cells from ...
    In this study, it was identified that exogenous supplementation of RA can promote the growth of cytodendrites of differentiated neuronal cells at early stage ...
  39. [39]
    Retinoic acid induces neuronal differentiation of a cloned human ...
    Retinoic acid causes human embryonal carcinoma cells to differentiate into neurons, forming clusters with axon bundles, and expressing tetanus toxin receptors.
  40. [40]
    Restriction of retinoic acid activity by Cyp26b1 is required for proper ...
    Nov 15, 2008 · Knockout of Cyp26b1 in mouse causes severe limb defects that have been attributed to a combination of shifts in the proximodistal patterning of ...
  41. [41]
    Craniosynostosis and multiple skeletal anomalies in ... - PubMed
    Nov 11, 2011 · Excess exogenous retinoic acid (RA) has been well documented to have teratogenic effects in the limb and craniofacial skeleton.
  42. [42]
    Generating retinoic acid gradients by local degradation during ...
    Cyp26 enzymes rapidly catabolize RA into inactive polar metabolites that can be cleared by the cell. While cells that produce RA typically do not express Cyp26 ...
  43. [43]
    Impact of Retinoic Acid on Immune Cells and Inflammatory Diseases
    In general, the use of retinoids in immune-mediated skin diseases has been highly beneficial for the patients.
  44. [44]
    Retinoic Acid and Germ Cell Development in the Ovary and Testis
    Retinoic acid (RA), a derivative of vitamin A, is critical for the production of oocytes and sperm in mammals. These gametes derive from primordial germ cells, ...
  45. [45]
    Resistin-like molecule α provides vitamin A-dependent antimicrobial ...
    Here, we identify resistin-like molecule α (RELMα) as a skin antimicrobial protein that is essential for vitamin A-dependent resistance to skin infection.
  46. [46]
    Vitamin A: A Key Inhibitor of Adipocyte Differentiation - PMC
    4. Retinoic Acid and Adipogenesis · Retinoids are potent inhibitors of adipocyte differentiation depending on the differentiation stage, RA concentration, and ...2. Vitamin A · 6. Pref-1 And Sox9 · Abbreviations
  47. [47]
    Retinoid Receptors in Bone and Their Role in Bone Remodeling
    It has been known for many years that hypervitaminosis A promotes skeleton fragility by increasing osteoclast formation and decreasing cortical bone mass.
  48. [48]
    20 Foods That Are High in Vitamin A - Healthline
    What animal foods are high in vitamin A? Vitamin A1, also known as retinol, is only found in animal-sourced foods, such as oily fish, liver, cheese, and butter.Missing: occurrence | Show results with:occurrence
  49. [49]
    [PDF] Beta carotene content - NIH Office of Dietary Supplements
    Cooked sweet potato (boiled, without skin) has 328 µg beta carotene per 1 cup, while dehydrated carrots have 74 µg per 1 cup.
  50. [50]
    Top 10 Foods Highest in Beta Carotene
    Nov 10, 2024 · 1. Baked Sweet Potatoes + Add. Beta-carotene per Cup, Beta-carotene per 100g, Beta-carotene per 200 Calories. 23018mcg (213% RDA), 11509mcg · 2.
  51. [51]
    Vitamin A deficiency - World Health Organization (WHO)
    Even mild, subclinical deficiency can be a problem, because it may increase children's risk for respiratory and diarrhoeal infections, decrease growth rates, ...
  52. [52]
    The Human Enzyme That Converts Dietary Provitamin A ...
    β-Carotene 15–15′-oxygenase (BCO1) catalyzes the oxidative cleavage of dietary provitamin A carotenoids to retinal (vitamin A aldehyde).
  53. [53]
    Enzymology of Vertebrate Carotenoid Oxygenases - PMC
    Thus, BCO1 is the enzyme responsible for the conversion of provitamin A carotenoids to vitamin A. It also cleaves the 15,15' bond of β-apocarotenals to yield ...
  54. [54]
    New insights and changing paradigms in the regulation of vitamin A ...
    The oxidation of retinol to retinal and its reversible interconversion, which are mediated predominantly by RDH10 and DHRS3 respectively, have now been firmly ...
  55. [55]
    Retinoic acid biosynthesis catalyzed by retinal dehydrogenases ...
    The last step of retinoic acid biosynthesis is irreversibly catalyzed by the NAD-dependent retinal dehydrogenases (RALDH), which are members of the aldehyde ...
  56. [56]
    Enzymatic Metabolism of Vitamin A in Developing Vertebrate Embryos
    Dec 15, 2016 · The reversible first step in conversion of the precursor vitamin A to the active retinoid RA is mediated by retinol dehydrogenase 10 (RDH10) ...
  57. [57]
    Biological Functions of RBP4 and Its Relevance for Human Diseases
    Mar 11, 2021 · Hepatic retinol mobilization by RBP4. Most of liver retinoids are stored as retinyl esters in hepatic stellate cells in a LRAT-dependent manner.Receptors For Rbp4 · Rbp4 Catabolism · Rbp4 Loss-And...
  58. [58]
    Acute retinol mobilization by retinol-binding protein 4 in mouse liver ...
    Hepatocytes secrete retinol-binding protein 4 (RBP4) into circulation, thereby mobilizing vitamin A from the liver to provide retinol for extrahepatic ...Hepatic Fgf21 Overexpression... · Fgf21 Increases Rbp4 And Rar... · Fgf21 Induces Depot-Specific...
  59. [59]
    Hepatic Retinyl Ester Hydrolases and the Mobilization of Retinyl ...
    Dec 27, 2016 · These hepatic vitamin A stores are known to be mobilized under times of insufficient dietary vitamin A intake but also under pathological conditions.3. Hepatic Retinyl Ester... · 3.2. Re Hydrolases Of... · 3.3. Re Hydrolases Of Other...
  60. [60]
    Biochemical and Physiological Importance of the CYP26 Retinoic ...
    The 4-OH-RA can be further oxidized to 4-oxo-RA while the 18-OH-RA and 16-OH-RA metabolites likely undergo glucuronidation or sequential hydroxylation by CYP26 ...
  61. [61]
    The role of CYP26 enzymes in retinoic acid clearance - PMC - NIH
    It has been proposed that cytochrome P450 family 26 (CYP26) enzymes have a role in determining the cellular exposure to RA by inactivating RA in cells that do ...
  62. [62]
    RETINOIC ACID SYNTHESIS AND DEGRADATION - PMC
    RA is produced in two sequential oxidative steps: first, retinol is oxidized reversibly to retinaldehyde, and then retinaldehyde is oxidized irreversibly to RA.
  63. [63]
    Vitamin A Update: Forms, Sources, Kinetics, Detection, Function ...
    May 18, 2021 · Vitamin A is a group of vital micronutrients widely present in the human diet. Animal-based products are a rich source of the retinyl ester form of the vitamin.
  64. [64]
    Vitamin A - StatPearls - NCBI Bookshelf
    Feb 19, 2025 · Preformed vitamin A (retinol and retinyl ester) is derived from animal products such as meat, dairy, and fish. Provitamin A (β-carotene), which ...Vitamin A · Indications · Administration<|separator|>
  65. [65]
    Isotretinoin - StatPearls - NCBI Bookshelf
    Mar 4, 2025 · Metabolism: Isotretinoin is primarily metabolized in the liver by the cytochrome P450 enzymes CYP2C8, CYP2C9, CYP3A4, and CYP2B6.
  66. [66]
    Retinoic Acid Actions Through Mammalian Nuclear Receptors - PMC
    Retinoids bind to six distinct nuclear receptors in mammals, altering the transcriptional activity of these transcription factors from repressors to activators ...
  67. [67]
    Retinoic Acid Actions through Mammalian Nuclear Receptors
    The retinoid X receptor (RXR) activates transcription of target genes in response to its natural ligand, 9-cis retinoic acid (9cRA), and a no. of RXR ...
  68. [68]
    Inhibition of Cell Proliferation and Induction of Apoptosis by the ...
    Mar 28, 1997 · The specificity with which AHPN and several other retinoids induce growth arrest and p21 expression in lung carcinoma cells indicates that the ...
  69. [69]
    Retinoic acid regulates cell cycle progression and cell differentiation ...
    However, despite a general under-standing that retinoids often induce cells to cease or slow their rate of proliferation and to assume a more mature phenotype, ...
  70. [70]
    13-cis Retinoic acid induces apoptosis and cell cycle arrest in ...
    13-cis RA causes cell cycle arrest and induces apoptosis in SEB-1 sebocytes by a RAR-independent mechanism, which contributes to its sebosuppressive effect and ...
  71. [71]
    Vitamin A and retinoid signaling: genomic and nongenomic effects
    (B) Vitamin A bound to RBP binds to the extracellular moiety of Stra6 and triggers the phosphorylation of its cytosolic domain. Phosphorylated STRA6 recruits ...Retinoic Acid And Other... · Ra Binding To Fatty... · Rar Phosphorylation
  72. [72]
    STRA6: role in cellular retinol uptake and efflux - PMC - NIH
    STRA6 is a transmembrane pore which transports vitamin A bidirectionally between extra- and intracellular retinoid binding proteins.
  73. [73]
    Adapalene - StatPearls - NCBI Bookshelf - NIH
    The adamantane nucleus is the chemical moiety that allows adapalene to attach to RAR-beta and RAR-gamma. This complex binds DNA through retinoic acid ...Continuing Education Activity · Indications · Mechanism of Action · Adverse Effects
  74. [74]
    Adapalene: Uses, Interactions, Mechanism of Action - DrugBank
    Adapalene binds to retinoic acid receptor (RAR)-beta and RAR-gamma; this ... selective RARgamma agonist for the treatment of acne. Bioorg Med Chem Lett ...
  75. [75]
    Why Topical Retinoids Are Mainstay of Therapy for Acne - PMC
    Jun 5, 2017 · A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial.
  76. [76]
    Role of Oral Retinoids in Treatment of Acne Vulgaris With a ... - NIH
    Apr 23, 2023 · This review supports the use of oral retinoids, specifically isotretinoin, as an effective and well-tolerated acne vulgaris therapy option.
  77. [77]
    Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of ...
    Sep 1, 2019 · RESULTS: At week 12, mean percent reduction in inflammatory and noninflammatory lesion counts were 58.6% and 51.4% respectively compared with ...
  78. [78]
    Comparative Efficacy of Pharmacological Treatments for Acne Vulgaris
    The most effective treatment for acne is oral isotretinoin, followed by triple therapies containing a topical retinoid, BPO, and an antibiotic.
  79. [79]
    Human Skin Aging and the Anti-Aging Properties of Retinol - PMC
    Nov 4, 2023 · Topical retinoids have demonstrated promise in enhancing skin texture, diminishing fine lines, and augmenting the thickness of both the epidermal and dermal ...
  80. [80]
    A Stabilized 0.1% Retinol Facial Moisturizer Improves the ... - PubMed
    This study demonstrates that a formulation containing stabilized retinol is safe and effective to ameliorate the appearance of photoaged skin.
  81. [81]
    Acitretin - StatPearls - NCBI Bookshelf - NIH
    Acitretin has anti-inflammatory and anti-proliferative effects. The drug normalizes keratinocyte differentiation in the epithelium. Aciretin also hinders ...
  82. [82]
    Acute promyelocytic leukemia (APL): remaining challenges towards ...
    Dec 16, 2019 · More than 80-90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy.
  83. [83]
    Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    Jul 11, 2013 · All-trans retinoic acid (ATRA) with chemotherapy is the ... acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%.
  84. [84]
    Prevention of second primary tumors with isotretinoin in squamous ...
    Sep 20, 1990 · Conclusions: Daily treatment with high doses of isotretinoin is effective in preventing second primary tumors in patients who have been treated ...Missing: chemoprevention post-<|separator|>
  85. [85]
    Bexarotene - PubMed
    Bexarotene is a selective retinoid X receptor (RXR) agonist. It binds to, and activates RXRs which function as ligand-activated transcription factors that ...
  86. [86]
    Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits ...
    In addition all-trans-retinoic acid (RA), the most active form of vitamin A metabolites, has been shown to limit carcinogenesis in animal models and to trigger ...<|separator|>
  87. [87]
    Role of retinoic acid metabolizing cytochrome P450s, CYP26, in ...
    Auto-induction of atRA metabolism and resulting resistance to atRA is the best characterized mechanism of APL relapse. In clinical pharmacokinetic studies in ...
  88. [88]
    A randomized trial of vitamin A and vitamin E supplementation for ...
    The study found 15,000 IU/d of vitamin A had a beneficial effect, while 400 IU/d of vitamin E had an adverse effect on retinitis pigmentosa.
  89. [89]
    Treatment for Retinitis Pigmentosa Reported | National Eye Institute
    Most adults with blinding retinitis pigmentosa (RP) should take a daily, 15000 IU vitamin A supplement, based on results from a large, randomized clinical trial
  90. [90]
    (PDF) Retinoids: novel potential therapeutics in the pursuit of HIV-1 ...
    Aug 10, 2025 · Retinoic acid (RA) derivatives are promising therapeutics that may promote clearance HIV latent reservoir allowing for definitive cure.
  91. [91]
    The beneficial effects of treatment with all-trans-retinoic acid plus ...
    Corticosteroids are highly effective anti-inflammatory or immunosuppressive drugs used commonly to treat human systemic lupus erythematosus (SLE).
  92. [92]
    Successful Treatment With Retinoids in Patients With Lupus Nephritis
    We report a dramatic therapeutic response to ATRA in 2 patients with lupus nephritis. ATRA treatment rapidly improved clinical symptoms and laboratory findings.
  93. [93]
    SYSTEMIC RETINOIDS IN THE MANAGEMENT OF OF ...
    Acetretin, isotretinoin and, in the past etretinate, have provided the most effective therapy for ichthyosiform conditions.<|separator|>
  94. [94]
    Bone changes and their significance in children with ichthyosis on ...
    However, we have observed no evidence of skeletal toxicity in 42 children treated over an 11-year period.
  95. [95]
    Bone changes in children on long-term treatment with etretinate
    Retinoid hyperostosis: skeletal toxicity associated with long-term administration of 13cis-retinoic acid for refractory ichthyosis ... A serious side-effect of ...
  96. [96]
    Safety and pharmacokinetics of the non-hormonal male ... - Nature
    Jul 22, 2025 · The small molecule YCT-529 stops sperm production, and we are developing YCT-529 as a non-hormonal oral contraceptive for men. To study the ...
  97. [97]
    Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal ...
    Aug 12, 2025 · YCT-529 reversibly reduces sperm counts to infertility levels in mice and non-human primates. Mice mating studies demonstrated 99% ...
  98. [98]
    Vitamin A Toxicity - StatPearls - NCBI Bookshelf
    Sep 2, 2023 · Notably, 1 RAE is equivalent to 1 mcg of retinol or 3 International units (IU). The RDA for vitamin A is as follows: 700 RAE for adult women.
  99. [99]
    Low-dose isotretinoin therapy and blood lipid abnormality - NIH
    [15] In contrary, the present study showed that hypertriglyceridemia was present in near about 17% of patients, hypercholesterolemia was present in 5% patients.
  100. [100]
    Teratogenic effect of isotretinoin in both fertile females and males ...
    The risk of teratogenicity in infants exposed to isotretinoin in utero is estimated to be 20-35%. This includes numerous congenital defects including ...Missing: category | Show results with:category
  101. [101]
    Pregnancy and neonatal outcomes after periconceptional exposure ...
    However, isotretinoin has been identified as a teratogenic agent in animal experiments and is classified as a category X drug. Exposure to isotretinoin during ...<|control11|><|separator|>
  102. [102]
    Epidermal Hyperplasia and Elevated HB-EGF are More Prominent ...
    Aug 5, 2010 · The mechanism of retinoid dermatitis involves barrier disruption, cytokines, COX and HB-EGF induced epidermal hyperplasia. Although most of the ...Change In Tewl · Change In Ear Thickness · Fig. 7
  103. [103]
    iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) - FDA
    Dec 1, 2023 · The goals of the iPLEDGE REMS are to prevent fetal exposure to isotretinoin and to inform prescribers, pharmacists, and patients about isotretinoin's serious ...
  104. [104]
    iPLEDGE REMS - Home
    The iPLEDGE REMS is a safety program to manage the risk of isotretinoin's teratogenicity and to minimize fetal exposure.
  105. [105]
    Isotretinoin and other retinoids during pregnancy - March of Dimes
    There's no program like iPLEDGE for other oral retinoids. But if you're taking any oral retinoid, following the iPLEDGE rules can help prevent birth defects.
  106. [106]
    Acitretin and isotretinoin Interactions - Drugs.com
    Patients with preexisting hyperlipidemia may require closer monitoring during retinoid therapy, and adjustments made accordingly in their lipid-lowering regimen ...Missing: precautions | Show results with:precautions
  107. [107]
    Management of Hypertriglyceridemia in Patients Taking Isotretinoin
    Aug 29, 2025 · Isotretinoin is known to cause elevations in triglyceride levels as a common adverse effect. Proper monitoring includes: Baseline fasting ...Missing: precautions | Show results with:precautions
  108. [108]
    How to manage isotretinoin therapy in a patient with ... - Dr.Oracle
    Jul 28, 2025 · For patients with triglyceride levels of 2.6 mmol/L on isotretinoin therapy, continue isotretinoin with more frequent triglyceride monitoring ( ...Missing: precautions | Show results with:precautions
  109. [109]
    Isotretinoin and tetracycline Interactions - Drugs.com
    Combining these medications may increase the risk of a rare, but potentially serious, condition called pseudotumor cerebri caused by increased pressure in the ...Missing: vitamin | Show results with:vitamin
  110. [110]
    Tetracycline and Isotretinoin Drug Interaction - Empathia AI
    Summary. The combination of tetracycline and isotretinoin is contraindicated due to an increased risk of pseudotumor cerebri (benign intracranial hypertension).
  111. [111]
  112. [112]
    Relationships between structure and activity of retinoids - Nature
    Sep 9, 1976 · Sporn, M. B., Dunlop, N. M., Newton, D. L., and Smith, J. M., Fedn Proc., 35, 1332–1338 (1976). CAS Google Scholar. Goodman, D. S., Smith, J. E. ...Missing: paper | Show results with:paper
  113. [113]
    75 Years of Vitamin A Production: A Historical and Scientific ...
    Aug 14, 2023 · (11−13) In the early 1930s, the group of Karrer determined the structure of vitamin A. (14−17) After elucidation of the structure of β-carotene ...
  114. [114]
    The Synthesis of Rhodopsin from Vitamin A1 - PNAS
    The Synthesis of Rhodopsin from Vitamin A1. George Wald and Ruth HubbardAuthors Info & Affiliations. February 15, 1950. 36 (2) 92-102.Missing: original paper
  115. [115]
    [PDF] RETIN-A MICRO® (tretinoin) gel, for topical use - accessdata.fda.gov
    See full prescribing information for RETIN-A MICRO. RETIN-A MICRO® (tretinoin) gel, for topical use. Initial U.S. Approval: 1971. --------------------------- ...
  116. [116]
    Trifarotene: A Current Review and Perspectives in Dermatology - PMC
    Feb 26, 2021 · Retinoids have now reached the fourth generation, progressively reducing toxicity whilst increasing their efficacy. Trifarotene is a new fourth ...
  117. [117]
    A Real-World Approach to Trifarotene Treatment in Patients with ...
    Jan 9, 2025 · In this article, we review the main evidence supporting the use of trifarotene in patients with acne and acne sequelae and provide place-in-therapy suggestions.
  118. [118]
    Integrating Trifarotene and Topical Retinoids Into Acne and Acne ...
    Jul 16, 2025 · Trifarotene, a fourth-generation RAR-γ selective retinoid, shows efficacy in reducing atrophic scars and hyperpigmentation, especially in ...
  119. [119]
    Retinol Binding Protein 4 reactivates latent HIV-1 by triggering ...
    Oct 3, 2025 · This latent reservoir is already established early during acute HIV-1 infection and remarkably stable, even under long-term effective therapy.
  120. [120]
    Ginsenoside CK and retinol on UVA-induced photoaging exert the ...
    May 13, 2025 · Our results show that retinol, HPR and VAPA combined with ginsenoside CK have good anti-aging and irritation-reducing effects in vitro and in vivo.
  121. [121]
    Retinoic acid breakdown is required for proximodistal positional ...
    Jun 10, 2025 · Retinoic acid breakdown is required for proximodistal positional identity during axolotl limb regeneration. Nat Commun 16, 4798 (2025).
  122. [122]
    Notch3 enhances the synergistic effect of all-trans retinoic acid and ...
    Jun 22, 2025 · In this study, we confirmed the important role of Notch3 in PSC activation and found that ATRA and calcipotriol could regulate Notch3 expression.
  123. [123]
    Retinoid signaling in pancreas development, islet function, and ...
    Retinoid signaling in pancreas development, islet function, and disease. November 2024; Current Topics in Developmental Biology 161. DOI:10.1016/bs.ctdb.2024.10 ...